← Compound index
COMPOUND RECORD / DILEPT

DileptДилепт

GZR-123, an experimental peptidomimetic designed from a fragment of neurotensin, a signaling peptide. Human studies included psychiatric dose-finding and a comparison with risperidone.

CognitionPerformance
Source linked

What the studies found

Comparison in people · 2021

Dilept versus risperidone in a 28-day psychiatric comparison

WAIS-R digit-symbol coding
Reported difference in change −1.90 points, favoring Dilept under the authors’ sign conventionDay 28Reported interval −3.43 to −0.36
PANSS negative symptoms and grouped psychiatric symptoms
No statistically significant between-group differences in reported changesDay 28

A WAIS-R coding task favored Dilept by 1.90 points in the authors’ analysis. The PANSS negative-symptom subscale showed no significant advantage over risperidone.

Study notes · methods, sources and limitations

Participants or model 25 adults aged 19–54 with schizotypal disorder or pseudoneurotic schizophrenia, as described in the paper. Dilept: 15. Risperidone: 10.

Design Active-comparator study using the PANSS negative-symptom subscale, grouped psychiatric symptoms and WAIS-R testing.

Important limitations

  • Small comparison with symptom and cognitive endpoints. Benzodiazepine use complicates attribution. The paper may reuse the 15-person, 200 mg/day arm of the earlier Zakusov pilot.

Experimental and Clinical Pharmacology. 2021;84(8):3–12. · Indexed abstract

Original source or citation ↗

Study results and tables ↗

Comparison in people · 2017

Dose-ranging cognitive report from the 25-patient Dilept pilot

The report describes greater changes across WAIS measures at 200 mg/day. These 25 patients match the dose-finding cohort described in the 2020 paper.

Study notes · methods, sources and limitations

Participants or model 25 patients, mean age 33.4 ± 10.0 years, with ICD-10 F21.3. Dose groups: 5 at 60 mg/day, 5 at 120 mg/day and 15 at 200 mg/day. Seventy healthy volunteers provided reference test scores.

Design WAIS comparison within the phase II dose-finding pilot, with baseline healthy reference data.

Cognitive measures across doses
The authors reported larger improvements in psychomotor speed, attention and memory at 200 mg/day than at 60 or 120 mg/day.
Treatment groups
5, 5 and 15 patients across the ascending doses. Seventy healthy reference participants.

Important limitations

  • The healthy participants provided cognitive reference scores. They did not serve as a randomized treatment control. Dose groups were small and unequal.

Experimental and Clinical Pharmacology. 2017;80(8):8–14. · Publication record

Original source or citation ↗

Study results and tables ↗

Comparison in people · 2007

Dilept: lower anxiety scores during cold exposure

Study of multiple preparations

Dilept · cold exposure
State anxiety −24%; trait anxiety −19%Percentages as reported; no arm sample size, baseline score or verified between-arm effect.

Original proceedings: 86 men total across the Tabai chamber experiments.

Study notes · methods, sources and limitations

Participants or model 86 healthy men aged 18–22, considered fit for military service; Tabai climate chamber with cold, heat and simulated altitude

Design 86 healthy men aged 18–22, considered fit for military service; Tabai climate chamber with cold, heat and simulated altitude

Important limitations

  • Per-arm counts, doses and reliable between-arm comparisons are unavailable. Possible overlap with related journal reports.
  • Treatment allocation, masking, arm denominators and complete comparator data unavailable. The text says placebo and control measurements did not differ while printing p<0.05; this inconsistency cannot be resolved from the abstract. This report may overlap the 2007 journal reports or 2008 dissertation. The 86 participants are listed separately and excluded from the combined total.
  • The outcomes are condition-specific and largely qualitative. Use the journal record for its separate tables and route details, with possible cohort overlap kept visible.

Visceral Systems and Their Regulation, conference proceedings, p. 79 · Original conference abstract

Original source or citation ↗

Study results and tables ↗
01 / OVERVIEW

About Dilept

Names in this research collection

GZR-123

Identity / background source ↗

Research background

A neurotensin-related peptidomimetic (GZR-123), studied in a psychiatric dose-finding pilot, a risperidone comparison, animal pharmacokinetics and an occupational environment study.

More study findings

Animal research · 2009

Dilept formulation and metabolite exposure in rats

Absolute oral bioavailability of unformulated Dilept
Less than 1%
Time detected in plasma after oral treatment
Unchanged drug for at least 30 minutes. Two metabolites for more than 4 hours.

Unformulated oral Dilept had less than 1% absolute bioavailability in rats. The tablet improved oral exposure, and two metabolites remained detectable in blood for more than four hours.

Study notes · methods, sources and limitations

Participants or model Rats. The abstract does not provide group sizes.

Design HPLC–tandem mass spectrometry of Dilept and metabolites, with structural confirmation by chemical synthesis.

Important limitations

  • The abstract describes the tablet’s bioavailability result as a 22% improvement without clearly defining the basis of that percentage. These are formulation-specific rat data.

Experimental and Clinical Pharmacology. 2009;72(3):16–21. · Indexed abstract

Original source or citation ↗

Study results and tables ↗

Comparison in people · 2008

Climatic chamber workload by condition

Study of multiple preparations

Dilept · cold (n=16)
182 W during exposureThe author reports 12% higher than the historical untreated control.

Reported cycling work capacity in healthy men aged 20–24.

Study notes · methods, sources and limitations

Participants or model 301 men aged 20–24 across the full program. Selected tables compare 17 Cortexin, 18 Noopept, 17 Cerebrolysin and nine placebo participants, with historical controls in cold.

Design Tabai climatic chamber: −10°C with 2.5 m/s airflow, +45°C at 80% humidity, or 3,000 m simulated altitude. The abstract specifies 40 minutes for cold and heat and 90 minutes at altitude within a longer chamber session.

Important limitations

  • Related reports have overlapping results and group differences before exposure.
  • Pre-chamber values reflect the testing protocol and are not established drug-free baselines. Small groups and multiple outcomes limit interpretation. Related 2007 journal and conference reports share investigators, treatments and chamber conditions. Matching workload means indicate overlap.
  • The ledger uses the 301-person dissertation total once for these related reports.

Development and Study of New Meteoadaptogens, Kirov Military Medical Academy doctoral author abstract · Original dissertation author abstract

Original source or citation ↗

Study results and tables ↗

Animal research · 2009

Rat behavioral assays: dilept

Study of multiple preparations

Open-field behavior
Oleyl-Cortagen increased horizontal and vertical movement but halved hole explorationCortexin and Cerebrolysin increased horizontal movement; Dilept reduced horizontal and vertical movement.
Noopept, Semax, Selank and Dilept · vertical activity
Reduced vertical movements reportedCompound-specific rat behavior at the stated doses, not a measure of human alertness.
Porsolt immobility
Lower with Oleyl-Cortagen, Dilept and Cortexin; higher with Cerebrolysin, Semax, Cortagen and SelankThis unweighted behavior assay is distinct from loaded endurance swimming. Piracetam was inactive in the report.

Separate comparisons in an assay battery.

Study notes · methods, sources and limitations

Participants or model 192 Wistar rats, 200–220 g; methods describe at least 10–12 per group across a behavioral test battery

Design 192 Wistar rats, 200–220 g; methods describe at least 10–12 per group across a behavioral test battery

Reported study exposure
1 mg/kg intraperitoneally in the rat study.

Important limitations

  • Electrical self-stimulation and immobility do not measure athletic endurance.
  • Multiple behavioral comparisons, endpoint-specific group sizes and precise uncertainties need table recovery. Deltaran is the tested DSIP-containing formulation; no result for isolated DSIP can be inferred. The 2015 dissertation used separate doses/routes; it is not confirmed as independent replication of every experiment.
  • Opposing effects across assays are informative. Electrical self-stimulation and immobility are behavior readouts, and neither establishes improved human motivation or endurance.

Medical Academic Journal, 2009; publisher article 9357 · Original journal article

Original source or citation ↗

Study results and tables ↗

Observational study · 2020

[The peptide analogue of neurotensin with antipsychotic and pro-cognitive effects: results of the pilot clinical trial].

Psychiatric and cognitive measures
Reported favorable changes; no PANSS, CGI or WAIS-R deltas supplied

A 25-person Dilept pilot reported psychiatric and cognitive improvement, most evident at 200 mg/day; it did not provide numerical symptom-score changes in its abstract.

Study notes · methods, sources and limitations

Participants or model 25 patients with schizotypal disorder

Design 25 patients with schizotypal disorder; 14-day monotherapy phase with limited rescue phenazepam, followed by combination treatment if needed.

Participants
25; mean age 33.4 ± 10.0 years
Studied doses
60, 120 and 200 mg/day; strongest reported action at 200 mg/day

Important limitations

  • Small pilot with permitted or add-on phenazepam. The same 25 patients are described in the 2017 cognitive report. The 2021 active comparison may reuse the 15-person high-dose arm.
  • Small uncontrolled pilot with rescue and subsequent combination therapy; claims about superiority to other antipsychotics are not established by this design.

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · Publication record

Original source or citation ↗

Source for the reported results ↗

Study results and tables ↗

Comparison in people · 2007

Meteoadaptogenic properties of nootrop drugs

Study of multiple preparations

Noopept
Favorable psychological measures in heat and cold; physical efficiency reported in heatNo effect sizes in the publisher abstract.
Cortexin and Vinpotropil
Cortexin effects described in cold and hypoxia; Vinpotropil in cold and heatDistinct preparations and endpoints.
Dilept
Favorable psychological functional-state measures describedNo numerical comparison or group counts in the abstract.

The Academy abstract describes stressor-specific functional-state findings across four compounds, including Noopept. It emphasizes mental work capacity and heat/high-altitude adaptation.

Study notes · methods, sources and limitations

Participants or model Healthy men aged 20–24; −10°C, +45°C and hypoxia (reported pO₂ 109.9 mmHg)

Design Academy report on cold, heat and hypobaric hypoxia, with cohort overlap unresolved.

Important limitations

  • The current publisher record says 2007, issue 4, pp. 61–66; later bibliographies cite 2008. Original issue verification remains open. This abstract differs from the Eksp Klin Farmakol summary, including the Cortexin/cold account. Differences are preserved pending table-level review. Possible cohort overlap with the 2007 paper; not independent replication.
  • Related to the 86-man and 127-man reports. Avoid pooling or importing their doses and estimates.

Bulletin of the Russian Military Medical Academy. No. 4:61–66; date discrepancy noted · Bibliographic lead

Original source or citation ↗

Study results and tables ↗

Research updates ↗

Compound class
Environmental nootropic research
Research collection
Related nootropics & combinations · editorial grouping
Institutions in linked studies
See individual study records
Source review
Review dates and the material assessed are listed with each publication below.
02 / HOW TO READ THE RESEARCH

Understanding the evidence

Human research

Psychiatric dose-finding pilot and a risperidone comparison, with potential reuse of the high-dose arm

Study methods

Pilot monotherapy/add-on design, rodent studies and historical environmental comparisons

Independent replication

The 2017 and 2020 papers describe the same pilot cohort. The 2021 comparison may reuse its 15-person high-dose arm.

Source access

Original Russian journal PDF; selected methods checked

Safety evidence

Human long-term safety and operational protection not established

Open a topic for the evidence assessment.

More findings, background and history
RELATED PEPTIDE RESEARCH / UPDATED OCTOBER 2026

Connections in the research

The neurotensin-mimetic record now includes a 25-patient psychiatric pilot, rat work on its GZR-125 metabolite, and opioid-withdrawal experiments. These are distinct from the existing environmental-chamber comparison.

View the peptide family map and sources ↗

What remains unclear

The original report and protocol would clarify group sizes, background treatment and translation. Independent replication and equivalence to current products remain uncertain.

Human reports are linked; their presence does not establish effectiveness. Several publications can describe the same participants.

Browse original study records ↗
PATENT RESEARCH / COLLECTION UPDATED 7 NOVEMBER 2026

Patents and claimed inventions

These 1 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.

2011 · RU2420304C2 · Dilept: defined peptide-derived formulationFormulation · Example tablets/capsules are reported to meet pharmacopoeial requirements

Findings described in words

The patent reports producing solid dosage forms that meet stated quality requirements.

Formulation outcome
Example tablets/capsules are reported to meet pharmacopoeial requirementsA manufacturing claim supported by preparation examples, not a clinical response
Quality specifications
Capsule disintegration limit ≤20 minutes; impurity limits ≤0.5% individually and ≤1% totalThese are acceptance limits, not measured patient outcomes or observed batch values
All reported results, comparisons and limitations →

Formulation. The patent identifies a formulation involving N-caproyl-L-prolyl-L-tyrosine methyl ester.

Exact chemical identity matters; the formulation patent does not establish comparative antipsychotic efficacy.

Publication
RU2420304C2 ↗ · 2011-06-10
Earliest priority / filing
2009-01-15 / 2009-01-15
Original applicant / assignee
Учреждение Российской Академии Медицинских Наук Научно-Исследовательский Институт Фармакологии Имени В.В.Закусова Рамн
Indexed status
Not shown; official status unverified · checked 2026-11-06
Patent family
42685698 · family publications are related filings, not independent studies.
Original title, inventors and related publications

Pharmaceutical composition with antipsychotic action

Inventors: Сергей Борисович Середенин (RU); Сергей Борисович Середенин; Борис Михайлович Пятин (RU); Борис Михайлович Пятин; Нина Ивановна Авдюнина (RU); Нина Ивановна Авдюнина; Константин Викторович Алексеев (RU); Константин Викторович Алексеев; Любовь Николаевна Грушевская (RU); Любовь Николаевна Грушевская; Евгения Викторовна Блынская (RU); Евгения Викторовна Блынская; Раиса Филипповна Большакова (RU); Раиса Филипповна Большакова; Максим Владимирович Гусев (RU); Максим Владимирович Гусев; Ольга Михайловна Шендера (RU); Ольга Михайловна Шендера.

RU2420304C2

Original patent PDF ↗

Read source review →

Status is an indexed snapshot, not an official legal assessment. Search the patent collection and read the method →

03 / SOURCE RECORDS

Findings by study

Explore related research ↗

Comparison in people · 2021

Dilept versus risperidone in a 28-day psychiatric comparison

A WAIS-R coding task favored Dilept by 1.90 points in the authors’ analysis. The PANSS negative-symptom subscale showed no significant advantage over risperidone.

Study notes and original source
2021Human comparative studyEnglish abstract

Dilept versus risperidone in a 28-day psychiatric comparison

I. O. Bogdanova, T. S. Syunyakov, G. G. Neznamov, A. A. Chepelyuk, T. V. Kovalenok, O. A. Dorofeeva · Experimental and Clinical Pharmacology. 2021;84(8):3–12.

A WAIS-R coding task favored Dilept by 1.90 points in the authors’ analysis. The PANSS negative-symptom subscale showed no significant advantage over risperidone.

Results and tables

Reported findings and study design

Active-comparator study using the PANSS negative-symptom subscale, grouped psychiatric symptoms and WAIS-R testing.

Population or model 25 adults aged 19–54 with schizotypal disorder or pseudoneurotic schizophrenia, as described in the paper. Dilept: 15. Risperidone: 10.

Dose, route and schedule

Dilept 200 mg/day or risperidone 2 mg/day for 28 days. Phenazepam up to 2 mg was permitted as needed during days 1–14. From day 15, the report describes combinations with 0.5–2 mg of phenazepam.

Protocol source ↗ · Original journal abstract and comparison with the group’s 2017 and 2020 reports.

Results · Original journal abstract and comparison with the group’s 2017 and 2020 reports.
MeasureResultComparison, timing and statistics
WAIS-R digit-symbol codingReported difference in change −1.90 points, favoring Dilept under the authors’ sign conventionDay 28 · Reported interval −3.43 to −0.36
PANSS negative symptoms and grouped psychiatric symptomsNo statistically significant between-group differences in reported changesDay 28

Source for these results ↗ · Reviewed 2026-11-15

Population / setting
25 adults aged 19–54 with schizotypal disorder or pseudoneurotic schizophrenia, as described in the paper. Dilept: 15. Risperidone: 10.
Source reviewed
Original journal abstract and comparison with the group’s 2017 and 2020 reports.
Study limitations
  • Small comparison with symptom and cognitive endpoints. Benzodiazepine use complicates attribution. The paper may reuse the 15-person, 200 mg/day arm of the earlier Zakusov pilot.

Reviewed 2026-11-15.

Read the source ↗

Comparison in people · 2017

Dose-ranging cognitive report from the 25-patient Dilept pilot

The report describes greater changes across WAIS measures at 200 mg/day. These 25 patients match the dose-finding cohort described in the 2020 paper.

Study notes and original source
2017Human comparative studyFull text available

Dose-ranging cognitive report from the 25-patient Dilept pilot

T. V. Kovalenok, A. A. Shabanova, I. O. Bogdanova, T. S. Syunyakov, N. Y. Ivashkina, N. G. Bogdan, G. G. Neznamov · Experimental and Clinical Pharmacology. 2017;80(8):8–14.

The report describes greater changes across WAIS measures at 200 mg/day. These 25 patients match the dose-finding cohort described in the 2020 paper.

Results and tables

Reported findings and study design

WAIS comparison within the phase II dose-finding pilot, with baseline healthy reference data.

Dose, route and schedule

Dilept at 60, 120 or 200 mg/day for 28 days. Nineteen patients received phenazepam 0.5–2 mg/day starting on day 15.

Protocol source ↗ · Original journal PDF and cross-check against the 2020 pilot cohort.

Results · Original journal PDF and cross-check against the 2020 pilot cohort.
MeasureResultComparison, timing and statistics
Cognitive measures across dosesThe authors reported larger improvements in psychomotor speed, attention and memory at 200 mg/day than at 60 or 120 mg/day.
Treatment groups5, 5 and 15 patients across the ascending doses. Seventy healthy reference participants.

Source for these results ↗ · Reviewed 2026-11-15

Population / setting
25 patients, mean age 33.4 ± 10.0 years, with ICD-10 F21.3. Dose groups: 5 at 60 mg/day, 5 at 120 mg/day and 15 at 200 mg/day. Seventy healthy volunteers provided reference test scores.
Source reviewed
Original journal PDF and cross-check against the 2020 pilot cohort.
Study limitations
  • The healthy participants provided cognitive reference scores. They did not serve as a randomized treatment control. Dose groups were small and unequal.

Reviewed 2026-11-15.

Read the source ↗

Animal research · 2009

Dilept formulation and metabolite exposure in rats

Unformulated oral Dilept had less than 1% absolute bioavailability in rats. The tablet improved oral exposure, and two metabolites remained detectable in blood for more than four hours.

Study notes and original source
2009Animal / experimentalEnglish abstract

Dilept formulation and metabolite exposure in rats

V. P. Zherdev, S. S. Boiko, N. V. Mesonzhnik, S. A. Appolonova, G. N. Rodchenkov, R. U. Ostrovskaya, T. A. Gudasheva, S. B. Seredenin · Experimental and Clinical Pharmacology. 2009;72(3):16–21.

Unformulated oral Dilept had less than 1% absolute bioavailability in rats. The tablet improved oral exposure, and two metabolites remained detectable in blood for more than four hours.

Results and tables

Reported findings and study design

HPLC–tandem mass spectrometry of Dilept and metabolites, with structural confirmation by chemical synthesis.

Population or model Rats. The abstract does not provide group sizes.

Dose, route and schedule

Investigators compared oral and intravenous administration and reported an oral tablet dose of 200 mg/kg. The abstract does not specify the other arm doses.

Protocol source ↗ · Original indexed English abstract and pharmacokinetic findings.

Results · Original indexed English abstract and pharmacokinetic findings.
MeasureResultComparison, timing and statistics
Absolute oral bioavailability of unformulated DileptLess than 1%
Time detected in plasma after oral treatmentUnchanged drug for at least 30 minutes. Two metabolites for more than 4 hours.

Source for these results ↗ · Reviewed 2026-11-15

Population / setting
Rats. The abstract does not provide group sizes.
Source reviewed
Original indexed English abstract and pharmacokinetic findings.
Study limitations
  • The abstract describes the tablet’s bioavailability result as a 22% improvement without clearly defining the basis of that percentage. These are formulation-specific rat data.

Reviewed 2026-11-15.

Read the source ↗

Comparison in people · 2008

Ganapolsky climate chambers: Cortexin, Noopept and related comparators

Reported cycling work capacity in healthy men aged 20–24.

Study notes and original source
2008Human comparative studyRussian-language source

Ganapolsky climate chambers: Cortexin, Noopept and related comparators

· Original dissertation author abstract

Format: Author abstract transcription; methods and selected work-capacity tables. Full dissertation scan pending. · Reviewed: Reported methods, results and evidence limitations

V. P. Ganapolsky · Development and Study of New Meteoadaptogens, Kirov Military Medical Academy doctoral author abstract

In cold, Cortexin participants averaged 210 W versus 162 W with placebo. In heat, Noopept averaged 188 W versus 152 W with placebo.

Results and tables

Reported findings and study design

In cold, Cortexin participants averaged 210 W versus 162 W with placebo. In heat, Noopept averaged 188 W versus 152 W with placebo.

Tabai climatic chamber: −10°C with 2.5 m/s airflow, +45°C at 80% humidity, or 3,000 m simulated altitude. The abstract specifies 40 minutes for cold and heat and 90 minutes at altitude within a longer chamber session.

Population or model 301 men aged 20–24 across the full program. Selected tables compare 17 Cortexin, 18 Noopept, 17 Cerebrolysin and nine placebo participants, with historical controls in cold.

Dose, route and schedule

Intranasal amounts in the author abstract: Cortexin 0.5 mg, Noopept 0.1 mg, Cerebrolysin 43 mg, Dilept 0.1 mg, Semax 0.2 mg and Deltaran 20 mg. Oral Vinpotropil contained piracetam 400 mg and vinpocetine 5 mg. Arms and testing series differ.

Protocol source ↗ · Author abstract transcription; methods and selected work-capacity tables. Full dissertation scan pending.

Results · Author abstract transcription; methods and selected work-capacity tables. Full dissertation scan pending.
MeasureResultComparison, timing and statistics
Cortexin · cold (n=17)155 → 210 W vs 159 → 162 W with placeboBefore chamber to during exposure; the 210 W mean is marked p<0.05 versus placebo and historical controls.
Noopept · heat (n=18)182 → 188 W vs 164 → 152 W with placeboBefore chamber to during exposure; the 188 W mean is marked p<0.05 versus placebo.
Cortexin · simulated altitude170 → 170 W vs 162 → 154 W with placebo
Cerebrolysin · heat (n=17)194 → 138 W vs 164 → 152 W with placebo
Dilept · cold (n=16)182 W during exposureThe author reports 12% higher than the historical untreated control.
Semax · cold (n=17)195 → 161 WSeparate comparison. The in-chamber group mean was near control.
Deltaran · cold (n=18)196 → 217 WSeparate comparison. The author reports a significant increase from the pre-chamber measure.
Selected in-chamber PWC₁₇₀ means (W)
Selected in-chamber PWC₁₇₀ means (W)
GroupColdHeatSimulated altitude
Cortexin (n=17)210155170
Noopept (n=18)189188197
Cerebrolysin (n=17)157138152
Placebo (n=9)162152154

PWC₁₇₀ is the cycling workload at 170 beats/min. These are descriptive group means.

The ledger uses the 301-person dissertation total once for these related reports.

Source for these results ↗ · Reviewed 2026-11-17

Population / setting
301 men aged 20–24 across the full program. Selected tables compare 17 Cortexin, 18 Noopept, 17 Cerebrolysin and nine placebo participants, with historical controls in cold.
Source reviewed
Author abstract transcription; methods and selected work-capacity tables. Full dissertation scan pending.
Study limitations
  • Pre-chamber values reflect the testing protocol and are not established drug-free baselines. Small groups and multiple outcomes limit interpretation.
  • Related 2007 journal and conference reports share investigators, treatments and chamber conditions. Matching workload means indicate overlap.

Reviewed 2026-11-17.

Read the source ↗

Comparison in people · 2007

Ganapolsky’s 86-man climate-chamber conference report

Original proceedings: 86 men total across the Tabai chamber experiments.

Study notes and original source
2007Human comparative studyFull text available

Ganapolsky’s 86-man climate-chamber conference report

· Original conference abstract

Format: Original proceedings PDF, printed p. 79 · Reviewed: Reported methods, results and evidence limitations

V. P. Ganapolsky, P. V. Aleksandrov, A. A. Elistratov · Visceral Systems and Their Regulation, conference proceedings, p. 79

The abstract reports Dilept anxiety changes in cold, Noopept arithmetic-task findings in heat, and qualitative Cortexin work-capacity changes at simulated altitude.

Results and tables

Reported findings and study design

The abstract reports Dilept anxiety changes in cold, Noopept arithmetic-task findings in heat, and qualitative Cortexin work-capacity changes at simulated altitude.

86 healthy men aged 18–22, considered fit for military service; Tabai climate chamber with cold, heat and simulated altitude

Population or model 86 healthy men aged 18–22, considered fit for military service; Tabai climate chamber with cold, heat and simulated altitude

Protocol information

The conference abstract does not report doses, routes, timing or arm sizes. The 127-person journal report describes its own methods.

Protocol source ↗ · Entire original conference abstract checked in the proceedings PDF; no full study report or tables accompany it

Results · Entire original conference abstract checked in the proceedings PDF; no full study report or tables accompany it
MeasureResultComparison, timing and statistics
Dilept · cold exposureState anxiety −24%; trait anxiety −19%Percentages as reported; no arm sample size, baseline score or verified between-arm effect.
Noopept · heat exposureArithmetic errors reportedly fell to zeroThe task denominator, absolute starting error count and placebo contrast were not supplied.
Noopept · cold and heatFavorable self-rated functional state; less anxiety describedDifferent anxiety measures across conditions; no complete estimates.
Cortexin · simulated altitudeHigher work-capacity indices describedThe conference abstract does not provide magnitudes or uncertainty. Psychological effects were described as smaller than with Dilept or Noopept.
Placebo comparatorNarrative and p-value conflict“Did not differ” is accompanied by p<0.05. No correction inferred.

The outcomes are condition-specific and largely qualitative. Use the journal record for its separate tables and route details, with possible cohort overlap kept visible.

Source for these results ↗ · Reviewed 2026-11-08

Population / setting
86 healthy men aged 18–22, considered fit for military service; Tabai climate chamber with cold, heat and simulated altitude
Source reviewed
Entire original conference abstract checked in the proceedings PDF; no full study report or tables accompany it
Study limitations
  • Treatment allocation, masking, arm denominators and complete comparator data unavailable.
  • The text says placebo and control measurements did not differ while printing p<0.05; this inconsistency cannot be resolved from the abstract.
  • This report may overlap the 2007 journal reports or 2008 dissertation. The 86 participants are listed separately and excluded from the combined total.

Reviewed 2026-11-08.

Read the source ↗

Animal research · 2009

Shabanov’s rat peptide behavior comparison: Oleyl-Cortagen and Cortexin

Separate comparisons in an assay battery.

Study notes and original source
2009Animal / experimentalFull text available

Shabanov’s rat peptide behavior comparison: Oleyl-Cortagen and Cortexin

· Original journal article

Format: Publisher full-text methods and results narrative; original PDF tables not recovered · Reviewed: Reported methods, results and evidence limitations

P. D. Shabanov et al. · Medical Academic Journal, 2009; publisher article 9357

Oleyl-Cortagen and Cortexin increased hypothalamic self-stimulation by 32% and 23%, respectively. Cortagen and Cerebrolysin did not change this outcome; other behavioral assays differed.

Results and tables

Reported findings and study design

Oleyl-Cortagen and Cortexin increased hypothalamic self-stimulation by 32% and 23%, respectively. Cortagen and Cerebrolysin did not change this outcome; other behavioral assays differed.

192 Wistar rats, 200–220 g; methods describe at least 10–12 per group across a behavioral test battery

Population or model 192 Wistar rats, 200–220 g; methods describe at least 10–12 per group across a behavioral test battery

Dose, route and schedule

Intraperitoneal doses: 1 mg/kg Cortexin, Cerebrolysin, Cortagen, Oleyl-Cortagen, Noopept and Dilept; 0.1 mg/kg Deltaran, Semax and Selank; piracetam 200 mg/kg. General behavior tests 30–40 minutes post-dose; self-stimulation measured 15–20 minutes post-dose.

Protocol source ↗ · Publisher full-text methods and results narrative; original PDF tables not recovered

Results · Publisher full-text methods and results narrative; original PDF tables not recovered
MeasureResultComparison, timing and statistics
Oleyl-Cortagen · self-stimulation+32% in lateral-hypothalamic pedal pressesReported relative increase, not an endurance or strength endpoint.
Cortexin · self-stimulation+23% in lateral-hypothalamic pedal pressesReported relative increase; no direct statistical test versus Oleyl-Cortagen supplied in narrative.
Cortagen and Cerebrolysin · self-stimulationNo change reported in pedal-press frequencyAt the systemic doses in this article; does not contradict the separate central-dose comparisons.
Open-field behaviorOleyl-Cortagen increased horizontal and vertical movement but halved hole explorationCortexin and Cerebrolysin increased horizontal movement; Dilept reduced horizontal and vertical movement.
Noopept, Semax, Selank and Dilept · vertical activityReduced vertical movements reportedCompound-specific rat behavior at the stated doses, not a measure of human alertness.
Porsolt immobilityLower with Oleyl-Cortagen, Dilept and Cortexin; higher with Cerebrolysin, Semax, Cortagen and SelankThis unweighted behavior assay is distinct from loaded endurance swimming. Piracetam was inactive in the report.
Deltaran · groomingGrooming reactions increasedThe report tested Deltaran, a DSIP-containing formulation; this observation is not assigned to isolated DSIP.

Opposing effects across assays are informative. Electrical self-stimulation and immobility are behavior readouts, and neither establishes improved human motivation or endurance.

Source for these results ↗ · Reviewed 2026-11-08

Population / setting
192 Wistar rats, 200–220 g; methods describe at least 10–12 per group across a behavioral test battery
Source reviewed
Publisher full-text methods and results narrative; original PDF tables not recovered
Study limitations
  • Multiple behavioral comparisons, endpoint-specific group sizes and precise uncertainties need table recovery.
  • Deltaran is the tested DSIP-containing formulation; no result for isolated DSIP can be inferred.
  • The 2015 dissertation used separate doses/routes; it is not confirmed as independent replication of every experiment.

Reviewed 2026-11-08.

Read the source ↗

Experiment described in a patent · 2011

Dilept: defined peptide-derived formulation — RU2420304C2

The patent reports producing solid dosage forms that meet stated quality requirements.

Study notes and original source
2011Patent / reported experimentsFull text available

Dilept: defined peptide-derived formulation — RU2420304C2

Patent-defined substance or composition · Patent publication

Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.

Сергей Борисович Середенин (RU), Сергей Борисович Середенин, Борис Михайлович Пятин (RU), Борис Михайлович Пятин, Нина Ивановна Авдюнина (RU), Нина Ивановна Авдюнина, Константин Викторович Алексеев (RU), Константин Викторович Алексеев, Любовь Николаевна Грушевская (RU), Любовь Николаевна Грушевская, Евгения Викторовна Блынская (RU), Евгения Викторовна Блынская, Раиса Филипповна Большакова (RU), Раиса Филипповна Большакова, Максим Владимирович Гусев (RU), Максим Владимирович Гусев, Ольга Михайловна Шендера (RU), Ольга Михайловна Шендера · RU2420304C2 · patent family 42685698

The patent reports producing solid dosage forms that meet stated quality requirements.

Results and tables

Reported patent results

Findings described in words

The patent reports producing solid dosage forms that meet stated quality requirements.

Dilept formulation/process examples and pharmacopoeial quality specifications; no clinical antipsychotic comparison.

Population or model Dilept formulation/process examples and pharmacopoeial quality specifications; no clinical antipsychotic comparison.

Results · Preparation examples and quality-standard Tables 2–3; specifications clearly labeled.
MeasureResultComparison, timing and statistics
Formulation outcomeExample tablets/capsules are reported to meet pharmacopoeial requirementsA manufacturing claim supported by preparation examples, not a clinical response
Quality specificationsCapsule disintegration limit ≤20 minutes; impurity limits ≤0.5% individually and ≤1% totalThese are acceptance limits, not measured patient outcomes or observed batch values

The table reports product specifications. Actual batch measurements are not independently extracted here.

Source for these results ↗ · Reviewed 2026-11-06

Population / setting
Dilept formulation/process examples and pharmacopoeial quality specifications; no clinical antipsychotic comparison.
Source reviewed
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
  • Exact chemical identity matters; the formulation patent does not establish comparative antipsychotic efficacy.
  • The table reports product specifications. Actual batch measurements are not independently extracted here.
  • Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
  • Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.

Reviewed 2026-11-06.

Read the source ↗

Observational study · 2020

[The peptide analogue of neurotensin with antipsychotic and pro-cognitive effects: results of the pilot clinical trial].

A 25-person Dilept pilot reported psychiatric and cognitive improvement, most evident at 200 mg/day; it did not provide numerical symptom-score changes in its abstract.

Study notes and original source
2020Uncontrolled human reportFull text available

[The peptide analogue of neurotensin with antipsychotic and pro-cognitive effects: results of the pilot clinical trial].

Neznamov GG, Bogdanova IO, Sunyakov TS, Dorofeeva OA, Kovalenok TV, Chepeluk AA · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

A 25-person Dilept pilot reported psychiatric and cognitive improvement, most evident at 200 mg/day; it did not provide numerical symptom-score changes in its abstract.

Results and tables

Reported findings and study design

A 25-person Dilept pilot reported psychiatric and cognitive improvement, most evident at 200 mg/day; it did not provide numerical symptom-score changes in its abstract.

25 patients with schizotypal disorder; 14-day monotherapy phase with limited rescue phenazepam, followed by combination treatment if needed.

Dose, route and schedule

Dilept: 60, 120 or 200 mg/day for 14 days as monotherapy. Single 2 mg doses of phenazepam were permitted as rescue treatment; subsequent combination treatment must be distinguished from the monotherapy phase.

Protocol source ↗ · Indexed publication abstract

Results · Primary-publication indexed abstract; no full-text table appraisal
MeasureResultComparison, timing and statistics
Psychiatric and cognitive measuresReported favorable changes; no PANSS, CGI or WAIS-R deltas supplied
Participants25; mean age 33.4 ± 10.0 years
Studied doses60, 120 and 200 mg/day; strongest reported action at 200 mg/day

Small uncontrolled pilot with rescue and subsequent combination therapy; claims about superiority to other antipsychotics are not established by this design.

Source for these results ↗ · Reviewed 2026-11-01

Population / setting
25 patients with schizotypal disorder
Source reviewed
Original full paper and 2017 dose-finding publication, with cohort comparison.
Study limitations
  • Small pilot with permitted or add-on phenazepam. The same 25 patients are described in the 2017 cognitive report. The 2021 active comparison may reuse the 15-person high-dose arm.

Reviewed 2026-11-15.

Read the source ↗

Animal research · 2013

[The study of procognitive effect of the potential antipsychotic, Dilept and its main metabolite, GZR-125 at the novel objects recognition test in rats].

Dilept and its metabolite GZR-125 were compared in rat novel-object recognition experiments, extending the neurotensin-mimetic program beyond the parent compound.

Study notes and original source
2013Animal / experimentalEnglish abstract

[The study of procognitive effect of the potential antipsychotic, Dilept and its main metabolite, GZR-125 at the novel objects recognition test in rats].

Gorelov PI, Ostrovskaia RU, Sazonova NM · Eksperimental'naia i klinicheskaia farmakologiia

Dilept and its metabolite GZR-125 were compared in rat novel-object recognition experiments, extending the neurotensin-mimetic program beyond the parent compound.

Population / setting
Rats; experimental object recognition
Source reviewed
Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Study limitations
  • Preclinical findings do not establish human benefit or safety.
  • Abstract only. Full methods and independent replication remain unconfirmed.

Reviewed 2026-10-05.

Read the source ↗

Animal research · 2013

[Neurotensin NT (8- 13) dipeptide analog dilept increases the pain threshold and decreases the severity of morphine withdrawal syndrome in rats].

Dilept increased experimental pain thresholds and reduced morphine-withdrawal signs in rats. These findings are distinct from its small psychiatric pilot and occupational comparisons.

Pain threshold · 34% increase · p<0.01

Study notes and original source
2013Animal / experimentalEnglish abstract

[Neurotensin NT (8- 13) dipeptide analog dilept increases the pain threshold and decreases the severity of morphine withdrawal syndrome in rats].

Konstantinopol'skiĭ MA, Cherniakova IV, Kudrin VS, Klodt PM, Kolik LG, Gudasheva TA · Eksperimental'naia i klinicheskaia farmakologiia

Dilept increased experimental pain thresholds and reduced morphine-withdrawal signs in rats. These findings are distinct from its small psychiatric pilot and occupational comparisons.

Results and tables

Reported findings and study design

Rat tail-flick and morphine-withdrawal experiments; Dilept 1.6 mg/kg IP. Dependence induced with morphine 10–20 mg/kg IP for five days; 16 withdrawal signs scored.

Population or model Rats; experimental pain and morphine withdrawal

Results · Previously retrieved indexed abstract; numerical statements checked against the saved source text
MeasureResultComparison, timing and statistics
Pain threshold34% increasep<0.01
Withdrawal expression after single Dilept administration29.1% reductionp<0.01
Withdrawal expression after subchronic administration37.5% reductionp<0.01
Morphine analgesiaNo change with Dilept reported

Rat outcomes; not a human addiction-treatment regimen.

Source for these results ↗ · Reviewed 2026-10-29

Population / setting
Rats; experimental pain and morphine withdrawal
Source reviewed
Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Study limitations
  • Preclinical findings do not establish human benefit or safety.
  • Abstract only. Full methods and independent replication remain unconfirmed.

Reviewed 2026-10-05.

Read the source ↗

Review of earlier studies · 2018

Novel Technologies for Dipeptide Drugs Design and their Implantation.

The developers distinguish drug-inspired peptide design (Noopept and Dilept) from mimicking peptide/protein turns (GB-115 and GK-2). This is a historical design framework, not evidence of a shared clinical effect.

Study notes and original source
2018ReviewEnglish abstract

Novel Technologies for Dipeptide Drugs Design and their Implantation.

Gudasheva TA, Ostrovskaya RU, Seredenin SB · Current pharmaceutical design

The developers distinguish drug-inspired peptide design (Noopept and Dilept) from mimicking peptide/protein turns (GB-115 and GK-2). This is a historical design framework, not evidence of a shared clinical effect.

Population / setting
Developer account of medicinal-chemistry programs
Source reviewed
Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Study limitations
  • Developer review; claims require appraisal of each original study.
  • A shared design method does not establish equivalent biology or clinical benefit.

Reviewed 2026-10-05.

Read the source ↗

Controlled study in people · 2007

Meteoadaptogenic properties of peptide drugs in healthy volunteers

A program involving 127 healthy men compared four preparations under cold, heat and simulated altitude. Results varied by compound and test.

Study notes and original source
2007Clinical trial / comparisonFull text available

Meteoadaptogenic properties of peptide drugs in healthy volunteers

Format: Original journal PDF · Reviewed: Original publisher PDF, printed pages 42–44: legacy Cyrillic text decoded and selected results rows checked; visual table appraisal remains open

P. D. Shabanov, V. P. Ganapolsky, P. V. Aleksandrov · Eksp Klin Farmakol. 70(6):41–47

Noopept showed different performance and anxiety results under cold, heat and simulated altitude. The tables also distinguish Cortexin, Dilept and Vinpotropil.

Results and tables

Reported findings and study design

Noopept showed different performance and anxiety results under cold, heat and simulated altitude. The tables also distinguish Cortexin, Dilept and Vinpotropil.

127 healthy men across the program; active subgroups 10–20 and placebo 8–10 per stage. Program size is not the number given Noopept. Cold −10°C, heat +45°C and simulated altitude 3,000 m.

Population or model 127 healthy men aged 20–24 across a three-day environmental program; active groups reported as 10–20, placebo 8–10 per stage

Results · Original publisher PDF, printed pages 42–44: legacy Cyrillic text decoded and selected results rows checked; visual table appraisal remains open
MeasureResultComparison, timing and statistics
Noopept PWC170 in cold189 ± 10 versus 162 ± 2Placebo comparison in the cold chamber; source PWC170 values, units not added · Cold chamber · Source marks p<0.05 versus placebo and historical control
Noopept PWC170 in heat188 ± 6 versus 152 ± 1Placebo in the heat chamber; values checked in Table 2 · Heat chamber · Source marks p<0.05 versus placebo and historical control
Noopept arithmetic errors in heat0 ± 0 versus 0.8 ± 0.2Placebo in the heat chamber; test-specific errors · Heat chamber · Source significance marker versus placebo and historical control
Noopept state / trait anxiety in heat27 ± 3 / 27 ± 2Historical controls: 38 ± 2 / 34 ± 3; retain separate comparison identities · Heat chamber · Source marks p<0.05 versus placebo and historical control
Noopept PWC170 at simulated altitude197 ± 8 versus 154 ± 3Concurrent placebo; source values · Simulated 3,000 m · Source marks p<0.05 versus placebo and historical control
Noopept activity self-rating in heat5.9 ± 0.4 versus 4.2 ± 0.2Historical no-drug controls; the placebo value is separately shown in the table · Heat chamber
Cold chamber (−10°C): selected reported rows
Cold chamber (−10°C): selected reported rows
SettingPreparationGrip strength, kgPWC170Max oxygen uptake, LArithmetic actionsArithmetic errorsState anxietyTrait anxietyWell-beingActivityMood
Before chamberHistorical no-drug control46 ± 5153 ± 71.5 ± 0.0110.5 ± 1.21.2 ± 0.833 ± 331 ± 45.6 ± 0.34.9 ± 0.25.5 ± 0.5
Before chamberCortexin42 ± 1b155 ± 1b1.5 ± 0.0019.3 ± 1.71.5 ± 0.633 ± 331 ± 45.6 ± 0.45.3 ± 0.35.7 ± 0.5
Before chamberVinpotropil44 ± 3219 ± 9ab1.6 ± 0.01ab10.5 ± 1.02.1 ± 0.935 ± 332 ± 35.1 ± 0.35.0 ± 0.24.8 ± 0.5
Before chamberNoopept46 ± 3189 ± 3ab1.6 ± 0.01ab9.2 ± 1.20.4 ± 0.228 ± 2a27 ± 26.0 ± 0.96.3 ± 0.86.2 ± 0.7
Before chamberDilept42 ± 1b176 ± 1ab1.5 ± 0.0210.8 ± 1.80.8 ± 0.428 ± 2a28 ± 36.2 ± 0.75.4 ± 0.75.8 ± 0.3
Before chamberPlacebo48 ± 2159 ± 31.5 ± 0.019.7 ± 0.71.2 ± 0.631 ± 431 ± 35.6 ± 0.25.2 ± 0.35.6 ± 0.4
In chamberHistorical no-drug control45 ± 5165 ± 71.5 ± 0.019.8 ± 1.92.5 ± 0.438 ± 234 ± 35.0 ± 0.14.2 ± 0.25.4 ± 0.4
In chamberCortexin45 ± 3210 ± 7ab1.6 ± 0.02ab11.0 ± 1.90.3 ± 0.3ab38 ± 431 ± 45.2 ± 0.34.7 ± 0.45.1 ± 0.4
In chamberVinpotropil45 ± 2219 ± 13ab1.6 ± 0.02ab7.5 ± 0.8b0.5 ± 0.2ab36 ± 228 ± 3a4.9 ± 0.3b4.9 ± 0.15.1 ± 0.3
In chamberNoopept44 ± 2189 ± 10ab1.6 ± 0.02ab10.6 ± 1.51.6 ± 0.630 ± 3a27 ± 3a5.3 ± 0.36.0 ± 1.1a6.4 ± 0.8
In chamberDilept41 ± 1ab182 ± 5ab1.7 ± 0.01ab10.8 ± 1.90.8 ± 0.4a29 ± 3a28 ± 3a5.9 ± 0.5a5.3 ± 0.3a5.4 ± 0.6
In chamberPlacebo47 ± 2162 ± 21.5 ± 0.0110.0 ± 0.61.2 ± 0.533 ± 332 ± 35.4 ± 0.25.1 ± 0.45.5 ± 0.3

Reported central values with source uncertainty terms. a: p<0.05 versus no-drug control; b: p<0.05 versus placebo. Groups already differed before chamber entry. Historical controls are not concurrent randomized controls. Legacy text decoding was checked; full visual appraisal remains open.

Heat chamber (+45°C): selected reported rows
Heat chamber (+45°C): selected reported rows
SettingPreparationGrip strength, kgPWC170Max oxygen uptake, LArithmetic actionsArithmetic errorsState anxietyTrait anxietyWell-beingActivityMood
Before chamberHistorical no-drug control47 ± 3161 ± 41.5 ± 0.0110.5 ± 1.01.2 ± 0.833 ± 231 ± 45.6 ± 0.34.9 ± 0.25.5 ± 0.5
Before chamberCortexin43 ± 2181 ± 5ab1.6 ± 0.01ab11.5 ± 1.60.67 ± 0.235 ± 332 ± 35.1 ± 0.34.9 ± 0.24.8 ± 0.5
Before chamberVinpotropil45 ± 2189 ± 9ab1.6 ± 0.02ab10.7 ± 1.00.9 ± 0.429 ± 326 ± 35.9 ± 0.35.8 ± 0.2ab5.9 ± 0.3
Before chamberNoopept48 ± 3182 ± 3ab1.6 ± 0.01ab9.6 ± 1.30.8 ± 0.428 ± 3a27 ± 36.1 ± 0.2a6.1 ± 0.3ab6.4 ± 0.3ab
Before chamberDilept44 ± 2180 ± 7ab1.6 ± 0.01ab9.7 ± 1.80.7 ± 0.226 ± 3ab28 ± 35.4 ± 0.24.6 ± 0.5b4.9 ± 0.2
Before chamberPlacebo46 ± 2164 ± 21.5 ± 0.0111.0 ± 0.61.0 ± 0.132 ± 330 ± 35.5 ± 0.25.3 ± 0.25.5 ± 0.5
In chamberHistorical no-drug control47 ± 4151 ± 51.5 ± 0.019.8 ± 1.92.5 ± 0.438 ± 234 ± 35.0 ± 0.14.2 ± 0.25.4 ± 0.4
In chamberCortexin39 ± 1a155 ± 91.5 ± 0.029.6 ± 1.10.8 ± 0.7a36 ± 228 ± 3a4.9 ± 0.34.9 ± 0.1a5.1 ± 0.3
In chamberVinpotropil41 ± 2a202 ± 11ab1.6 ± 0.02ab10.3 ± 1.10.7 ± 0.4a31 ± 327 ± 3ab5.7 ± 0.2ab5.6 ± 0.2ab5.9 ± 0.3b
In chamberNoopept44 ± 3188 ± 6ab1.6 ± 0.01ab12.0 ± 1.40 ± 0ab27 ± 3ab27 ± 2ab6.2 ± 0.3ab5.9 ± 0.4ab6.2 ± 0.2ab
In chamberDilept42 ± 2174 ± 9ab1.5 ± 0.01ab10.5 ± 0.90.8 ± 0.5a27 ± 3ab28 ± 2ab5.1 ± 0.34.6 ± 0.2a4.9 ± 0.2
In chamberPlacebo42 ± 4152 ± 11.5 ± 0.0110.9 ± 1.30.8 ± 0.234 ± 333 ± 35.3 ± 0.24.9 ± 0.35.3 ± 0.2

Reported central values with source uncertainty terms. a: p<0.05 versus no-drug control; b: p<0.05 versus placebo. Groups already differed before chamber entry. Historical controls are not concurrent randomized controls. Legacy text decoding was checked; full visual appraisal remains open.

Simulated altitude (3,000 m): selected reported rows
Simulated altitude (3,000 m): selected reported rows
SettingPreparationGrip strength, kgPWC170Max oxygen uptake, LArithmetic actionsArithmetic errorsState anxietyTrait anxietyWell-beingActivityMood
Before chamberHistorical no-drug control46 ± 5151 ± 41.3 ± 0.0110.5 ± 1.01.2 ± 0.833 ± 231 ± 45.6 ± 0.34.9 ± 0.25.5 ± 0.5
Before chamberCortexin42 ± 2170 ± 5a1.6 ± 0.01ab9.7 ± 0.60.2 ± 0.1234 ± 332 ± 35.6 ± 0.35.1 ± 0.25.5 ± 0.3
Before chamberVinpotropil46 ± 2195 ± 5ab1.6 ± 0.01ab9.0 ± 0.50.5 ± 0.228 ± 327 ± 36.1 ± 0.2ab6.1 ± 0.3ab6.4 ± 0.3ab
Before chamberNoopept47 ± 3202 ± 3ab1.6 ± 0.01ab11.2 ± 0.60.2 ± 0.229 ± 326 ± 25.9 ± 0.35.8 ± 0.2a5.9 ± 0.3
Before chamberDilept41 ± 1181 ± 3ab1.6 ± 0.01ab14.2 ± 3.01.0 ± 0.627 ± 3a28 ± 26.2 ± 0.2ab5.8 ± 0.1a5.8 ± 0.2
Before chamberPlacebo46 ± 4162 ± 51.5 ± 0.0110.1 ± 0.80.6 ± 0.133 ± 330 ± 35.5 ± 0.25.6 ± 0.25.6 ± 0.4
In chamberHistorical no-drug control46 ± 4145 ± 51.3 ± 0.019.8 ± 1.93 ± 0.638 ± 234 ± 35.0 ± 0.14.2 ± 0.25.4 ± 0.4
In chamberCortexin41 ± 2170 ± 6ab1.6 ± 0.01ab9.7 ± 0.60.2 ± 0.2a34 ± 332 ± 35.4 ± 0.25.0 ± 0.2ab5.4 ± 0.2
In chamberVinpotropil44 ± 2196 ± 6ab1.6 ± 0.01ab10.4 ± 0.90.8 ± 0.3a27 ± 3ab27 ± 2ab6.2 ± 0.3ab5.9 ± 0.4ab6.2 ± 0.2ab
In chamberNoopept45 ± 3197 ± 8ab1.6 ± 0.01ab11.4 ± 1.72.2 ± 2.231 ± 4a27 ± 3ab5.7 ± 0.2a5.6 ± 0.2ab5.9 ± 0.3
In chamberDilept41 ± 1186 ± 6ab1.6 ± 0.01ab12.6 ± 2.50.6 ± 0.4a28 ± 3a28 ± 3ab6.3 ± 0.2ab5.6 ± 0.3ab6.1 ± 0.3ab
In chamberPlacebo46 ± 4154 ± 31.5 ± 0.019.5 ± 1.00.6 ± 0.233 ± 334 ± 35.4 ± 0.34.6 ± 0.15.6 ± 0.2

Reported central values with source uncertainty terms. a: p<0.05 versus no-drug control; b: p<0.05 versus placebo. Groups already differed before chamber entry. Historical controls are not concurrent randomized controls. Legacy text decoding was checked; full visual appraisal remains open.

Pre-chamber group differences, historical controls and unclear allocation limit attribution. The preparation-specific rows cannot be applied interchangeably to all four compounds. Experimental formulations and short chamber tasks do not establish safe performance during dangerous work.

Source for these results ↗ · Reviewed 2026-11-01

Population / setting
127 healthy men aged 20–24 across a three-day environmental program; active groups reported as 10–20, placebo 8–10 per stage
Source reviewed
Previously reviewed original journal PDF methods and selected tables. The separately recovered 86-man proceedings abstract is related; participant overlap remains unresolved.
Study limitations
  • Random allocation and blinding not established; historical controls and baseline differences limit attribution.
  • Exact arm-by-environment denominators remain unresolved; 127 is the program total, not Noopept enrollment.
  • Experimental intranasal peptide preparations are not equivalent to marketed oral products.
  • No validated protection from heat illness, operational accidents or long-term harm.
  • The Academy report may cover the same participants.

Reviewed 2026-11-08.

Read the source ↗

Comparison in people · 2007

Meteoadaptogenic properties of nootrop drugs

The Academy abstract describes stressor-specific functional-state findings across four compounds, including Noopept. It emphasizes mental work capacity and heat/high-altitude adaptation.

Study notes and original source
2007Human comparative studyBibliographic record

Meteoadaptogenic properties of nootrop drugs

V. P. Ganapolsky, A. A. Elistratov, P. V. Alexandrov, P. D. Shabanov, E. G. Mokeeva, E. A. Mitin, V. I. Kruglov · Bulletin of the Russian Military Medical Academy. No. 4:61–66; date discrepancy noted

The Academy abstract describes stressor-specific functional-state findings across four compounds, including Noopept. It emphasizes mental work capacity and heat/high-altitude adaptation.

Results and tables

Reported findings and study design

Qualitative, stressor-specific comparisons.

Academy report on cold, heat and hypobaric hypoxia, with cohort overlap unresolved.

Population or model Healthy men aged 20–24; −10°C, +45°C and hypoxia (reported pO₂ 109.9 mmHg)

Results · Publisher abstract; full tables not recovered
MeasureResultComparison, timing and statistics
NoopeptFavorable psychological measures in heat and cold; physical efficiency reported in heatNo effect sizes in the publisher abstract.
Cortexin and VinpotropilCortexin effects described in cold and hypoxia; Vinpotropil in cold and heatDistinct preparations and endpoints.
DileptFavorable psychological functional-state measures describedNo numerical comparison or group counts in the abstract.

Related to the 86-man and 127-man reports. Avoid pooling or importing their doses and estimates.

Source for these results ↗ · Reviewed 2026-11-08

Population / setting
Healthy men aged 20–24; −10°C, +45°C and hypoxia (reported pO₂ 109.9 mmHg)
Source reviewed
Publisher metadata and Russian abstract checked. A related manufacturer-hosted PDF is indexed, but direct download timed out; the PDF contents were not appraised.
Study limitations
  • The current publisher record says 2007, issue 4, pp. 61–66; later bibliographies cite 2008. Original issue verification remains open.
  • This abstract differs from the Eksp Klin Farmakol summary, including the Cortexin/cold account. Differences are preserved pending table-level review.
  • Possible cohort overlap with the 2007 paper; not independent replication.

Reviewed 2026-09-29.

Read the source ↗

Follow shared publications or research classes. These links do not establish equivalent effects between compounds.

Research collection curated by @PepMariner · editorial standards. Send a source correction ↗

Browse bibliography & PDFs ↗